<DOC>
	<DOCNO>NCT00833716</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim clinical trial investigate different degree renal impairment ( mild , moderate , severe end-stage renal disease ) affect pharmacokinetics NN9535 .</brief_summary>
	<brief_title>Effect Renal Impairment Pharmacokinetics NN9535</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject ) Subjects meeting predefined GFR ( glomerular filtration rate ) criterion ( estimate Cockcroft &amp; Gault formula ) renal function group Body Mass Index ( BMI ) equal less 40kg/m2 Known suspect allergy trial product ( ) relate product Renal transplant patient Certain cardiac problem ( heart failure , unstable angina , MI ( myocardial infarction ) within last 3 month ) Known current hepatic dysfunction severe hepatic disease last 12 month Female childbearing potential/breast feeding History alcoholism drug abuse Blood donation last 8 week prior study Past current history pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>